NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.
Laurent Lévy, CEO of Nanobiotix, and Deval Patrick, Governor of Massachusetts state, officially announced the opening of the company’s US affiliate during a ceremony on Friday September 19, 2014 at the US embassy in Paris, France, in the presence of Dr Susan Windham-Bannister, CEO and President of the Massachusetts Life Sciences Center.
The opening of the affiliate in Boston area is an important step for Nanobiotix’s international development strategy. The Massachusetts life science cluster is recognized worldwide for its critical number of high-quality academic centers and biopharma companies. Developing company’s operations in the Boston life sciences and nanomedicine hub will provide Nanobiotix with the access to the knowhow and high level expertise of the research.
This move is the next step of Nanobiotix’s International expansion, allowing the company to work closer to the US industrial and financial communities.
This environment should benefit to the company’s potential future development beyond NanoXray.
Laurent Lévy, Chief Executive Officer at Nanobiotix, commented: “The opening of a US affiliate is a key strategic step for Nanobiotix’s international ambitions. The Boston area is the ideal location for us to access new talent, innovative research and clinical expertise in the nanomedicine.”
To lead the development of the US affiliate, Patrick Tricoli has been appointed Vice President Corporate Development for Nanobiotix. Patrick has over 25 years’ experience within the pharmaceutical industry and joins Nanobiotix from Sanofi where he held a number of positions in both Corporate and Research and Development. In recent years Patrick has focused on international business development and partnering activities. He is a doctor of Pharmaceutical Sciences, he holds a master degree in Pharmacology and Pharmacokinetics, and he is an Executive MBA from ESCP Europe.
Patrick Tricoli commented: “Among hundreds of innovative projects I reviewed in my previous roles with both R&D and Business Development perspectives, I am firmly convinced that Nanobiotix’ disruptive approach could be the future of the healthcare industry. I am pleased to join this team with whom I share the same values, ambitions and passion.”